Key result
Simvastatin and ezetimibe did not reduce the primary composite of major cardiovascular events compared with placebo but reduced ischemic cardiovascular events.
Why the study?
Does statin therapy reduce the progression of aortic stenosis and improve cardiovascular outcomes in patients with aortic stenosis?
Does statin therapy reduce the progression of aortic stenosis and improve cardiovascular outcomes in patients with aortic stenosis?
Answers are grounded in this paper and cite their sources.
Statins may offer cardiovascular benefits in patients with aortic stenosis by reducing ischemic events, even if they do not slow the hemodynamic progression of the valve disease.
The excellent article by van Geldorp and co-workers demonstrated that >50% of their patients with symptomatic severe aortic stenosis did not undergo aortic valve replacement, but were instead offered conservative/medical treatment [1]. It would be interesting to know what constituted the ‘conservative/medical treatment’ in their study [1]. More specifically, it could be useful if the authors provided separate data regarding statin use in the medically treated patient subgroup [1]. Statins have been reported not only to reduce the progression of aortic stenosis, but also to improve cardiovascular outcomes in these patients [2]. The pathomechanism underlying this effect of statins is that aortic stenosis is an active process characterised by atherosclerosis-like lesions consisting of activated inflammatory cells (e.g., T lymphocytes, macrophages and mast cells), lipid/lipoprotein deposits, calcific nodules and cells with osteoblast-like activity [2,3]. An additional finding supporting this theory is that aortic stenosis progresses faster in patients with hypercholesterolaemia [2,3]. As statins are indicated both in the management of hypercholesterolaemia and atherosclerosis, it is possible that these agents comprise an effective way to retard the progression of aortic stenosis. A prospective study (mean follow-up: 73 ± 24 weeks) on 121 patients with moderate-to-severe aortic stenosis showed that treatment with rosuvastatin 20 mg per day (n = 61 patients) slowed the haemodynamic progression of aortic stenosis compared with statin non-use (n = 60 patients), as indicated by the change in aortic valve area (−0.05 ± 0.12 vs −0.10 ± 0.09 cm2 per year, respectively; p = 0.041) and the increase in aortic valve velocity (0.04 ± 0.38 vs 0.24 ± 0.30 m s−1 per year, respectively; p = 0.007) [4]. By contrast, the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study did not show an effect of intensive lipid-lowering therapy with simvastatin and ezetimibe on the course of aortic stenosis compared with placebo [5]. During a median follow-up of 52.2 months, the primary outcome (a composite of major cardiovascular events, including death from cardiovascular causes, aortic valve replacement, non-fatal myocardial infarction, hospitalisation for unstable angina pectoris, heart failure, coronary artery bypass grafting, percutaneous coronary intervention and non-haemorrhagic stroke) occurred in 35.3% versus 38.2% in the simvastatin–ezetimibe and placebo groups, respectively (hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.83–1.12; p = 0.59). Nevertheless, treatment with simvastatin and ezetimibe resulted in a reduction in the risk of ischaemic cardiovascular events (HR, 0.78; 95% CI, 0.63–0.97; p = 0.02), mainly through a decrease in the need for coronary artery bypass grafting procedures (HR, 0.68; 95% CI, 0.50–0.93; p = 0.02) [5]. Even if statins do not prove to reduce the progression of aortic stenosis, the reduction in the risk of ischaemic cardiovascular events is per se a sufficient reason to prescribe statins in these patients [2,4]. Statins have also been reported to reduce perioperative and long-term mortality rates, postoperative complications and hospital stay in patients undergoing aortic valve replacement [2]. Prescribing statins in patients with aortic stenosis offers several advantages and few (if any) disadvantages [2]. Thus, the exact ‘conservative/medical treatment’ (and more specifically the statin usage rates) in the medically treated patient subgroup probably deserves to be mentioned.
No takes yet. Share an insight, caveat, or question.
Kosmas I. Paraskevas (2009) conducted a letter in Aortic stenosis. Simvastatin and ezetimibe vs. Placebo was evaluated on Composite of major cardiovascular events, including death from cardiovascular causes, aortic valve replacement, non-fatal myocardial infarction, hospitalisation for unstable angina pectoris, heart failure, coronary artery bypass grafting, percutaneous coronary intervention and non-haemorrhagic stroke (HR 0.96, 95% CI 0.83-1.12, p=0.59). Simvastatin and ezetimibe did not reduce the primary composite of major cardiovascular events compared with placebo but reduced ischemic cardiovascular events.
Synapse has enriched 10 related papers. Consider them for comparative context: